Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1755 ARTÍCULOS , VIENDO DEL 646 AL 660

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease

Bateman RJ, Cummings J, Schobel S, Salloway S, Vellas B, Boada M, Black SE, Blennow K, Fontoura P, Klein G, Assunção SS, Smith J, Doody RS.

Alzheimers Res Ther. 2022 Nov 29;14(1):178. doi: 10.1186/s13195-022-01110-8.

Hypothesis on ontogenesis and pathophysiology of Alzheimer's disease

Schwab EDP, Queiroz R, Fiebrantz AKB, Bastos M, Bonini JS, Silva WCFND.

Einstein (Sao Paulo). 2022 Nov 25;20:eRW0170. doi: 10.31744/einstein_journal/2022RW0170. eCollection 2022.

Benefit and safety of antibiotics for Alzheimer's disease: Protocol for a systematic review and meta-analysis

Gao L, Shuai Y, Wen L, Zhang H, Zhang Y, Zhang X.

Medicine (Baltimore). 2022 Nov 25;101(47):e31637. doi: 10.1097/MD.0000000000031637.

Gamma frequency sensory stimulation in mild probable Alzheimer's dementia patients: Results of feasibility and pilot studies

Chan D, Suk HJ, Jackson BL, Milman NP, Stark D, Klerman EB, Kitchener E, Fernandez Avalos VS, de Weck G, Banerjee A, Beach SD, Blanchard J, Stearns C, Boes AD, Uitermarkt B, Gander P, Howard M 3rd, Sternberg EJ, Nieto-Castanon A, Anteraper S, Whitfield-Gabrieli S, Brown EN, Boyden ES, Dickerson BC, Tsai LH.

PLoS One. 2022 Dec 1;17(12):e0278412. doi: 10.1371/journal.pone.0278412. eCollection 2022.

Lecanemab for Alzheimer's disease: tempering hype and hope

The Lancet.

Lancet. 2022 Dec 3;400(10367):1899. doi: 10.1016/S0140-6736(22)02480-1.

The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer's disease

Du H, Meng X, Yao Y, Xu J.

Front Endocrinol (Lausanne). 2022 Nov 17;13:1033479. doi: 10.3389/fendo.2022.1033479. eCollection 2022.

Association between Porphyromonas Gingivalis and systemic diseases: Focus on T cells-mediated adaptive immunity

Li C, Yu R, Ding Y.

Front Cell Infect Microbiol. 2022 Nov 17;12:1026457. doi: 10.3389/fcimb.2022.1026457. eCollection 2022.

Self-Assembly of Amyloid-Beta (Aβ) Peptides from Solution to Near In Vivo Conditions

Nguyen PH, Sterpone F, Derreumaux P.

J Phys Chem B. 2022 Dec 15;126(49):10317-10326. doi: 10.1021/acs.jpcb.2c06375. Epub 2022 Dec 5.

Research Progress of Targeting Neuro-Immune Inflammation in the Treatment of Alzheimer's Disease

Chen H, Deng C, Meng Z, Meng S.

Front Biosci (Landmark Ed). 2022 Nov 25;27(11):312. doi: 10.31083/j.fbl2711312.

Natural Carotenoids as Neuroprotective Agents for Alzheimer's Disease: An Evidence-Based Comprehensive Review

Batool Z, Chen JH, Gao Y, Lu LW, Xu H, Liu B, Wang M, Chen F.

J Agric Food Chem. 2022 Dec 21;70(50):15631-15646. doi: 10.1021/acs.jafc.2c06206. Epub 2022 Dec 8.

Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's disease

Dhadda S, Kanekiyo M, Li D, Swanson CJ, Irizarry M, Berry S, Kramer LD, Berry DA.

Alzheimers Res Ther. 2022 Dec 9;14(1):182. doi: 10.1186/s13195-022-01129-x.

Effect of a Vegan Diet on Alzheimer's Disease

Katonova A, Sheardova K, Amlerova J, Angelucci F, Hort J.

Int J Mol Sci. 2022 Nov 29;23(23):14924. doi: 10.3390/ijms232314924.

Synthetic, Cell-Derived, Brain-Derived, and Recombinant β-Amyloid: Modelling Alzheimer's Disease for Research and Drug Development

Varshavskaya KB, Mitkevich VA, Makarov AA, Barykin EP.

Int J Mol Sci. 2022 Nov 30;23(23):15036. doi: 10.3390/ijms232315036.

Disease-Modifying Activity of Huperzine A on Alzheimer's Disease: Evidence from Preclinical Studies on Rodent Models

Yan YP, Chen JY, Lu JH.

Int J Mol Sci. 2022 Dec 3;23(23):15238. doi: 10.3390/ijms232315238.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias